Navigation Links
Advances in C. difficile research
Date:6/1/2008

New research into the toxins, virulence, spread and prevention of the superbug Clostridium difficile is reported in the June special issue of the Journal of Medical Microbiology. These findings will play a crucial role in providing us with ammunition in the fight against a sometimes deadly pathogen.

Clostridium difficile is found in the environment but is most common in hospitals. It can cause a serious hospital-acquired infection when antibiotics are used as they upset the balance of the normal gut flora, allowing C. difficile to grow and produce toxins. It is carried in the guts of 3% of healthy humans but carriage rates in hospital patients tend to be much higher and elderly people in hospitals, being treated with antibiotics are most at risk of developing infection. The bacteria produce spores when they encounter unfavourable conditions. Transmission of infection is through the ingestion of these spores which can survive on surfaces and floors for years and are resistant to many disinfectants and antiseptics, including alcohol hand gel.

Symptoms include diarrhoea, nausea, abdominal pain, loss of appetite, fever, bowel inflammation and possible perforation, which can be fatal. Only two antibiotics are regularly used to treat C. difficile infection: metronidazole and vancomycin, but relapse is a common problem following treatment. In 2004, a hypervirulent strain (C. difficile 027/NAP1/BI) was reported, which appears to make toxins more rapidly and at higher levels than other strains, as well as being resistant to many antibiotics, including fluoroquinolones.

Several studies in the Journal of Medical Microbiology look at the spread of C. difficile in different countries, including Austria and Korea. Research shows that the use of antibiotic increased the risk of outbreaks of the hypervirulent strain of C. difficile in the Netherlands. The issue also contains evidence to suggest that C. difficile could be spread between animals and humans researchers have isolated the bacterium from food animals in Slovenia.

Scientists investigated the effects of antibiotics, antigens and other agents on the virulence and pathogenicity of C. difficile. Toxins were also studied; research reveals some important information about the synthesis, processing and effects of different toxins. A new gene sequence has been discovered in the hypervirulent C. difficile 027 strain, which could be related to its increased virulence by affecting toxin binding.

The potential for a 'designer' probiotic for C. difficile is discussed. Professor Ian Poxton, former Editor-in-Chief of the Journal of Medical Microbiology said "this is an important approach that is hopefully much better than previously reported studies using commercially available yoghurt-like drinks, and certainly more palatable than 'faecal transplants'."


'/>"/>

Contact: Lucy Goodchild
l.goodchild@sgm.ac.uk
44-011-898-81843
Society for General Microbiology
Source:Eurekalert

Related medicine news :

1. Advances Aid Treatment, Diagnosis of Celiac Disease
2. Partnerships Effective Communicators of Cancer Advances
3. Partnership of academic centers and community hospitals effective model for disseminating advances
4. THE Aesthetic Show Advances $34 Billion Market
5. Singulex Advances Conversation on Personalized Medicine
6. TGrid 5.0 Advances Automatic, High-Quality Meshing Tools for Increased Productivity
7. Imaging Advances Map Brain Areas Affecting Mood
8. Recent Advances Make Sunscreen More Effective and Easier to Use
9. Treatment advances for fibroids, menopause
10. Breast reconstruction advances fix distortions left by lumpectomy
11. Breast Reconstruction Advances Fix Distortions Left by Lumpectomy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology: